Specialty pharmacy's role in REMS, FDA's new drug safety program; Focus on Fampridine-SR; FDA leadership promotes scientific integrity, quality standards
Class Action Lawsuit Filed Against CVS Caremark to Recoup DIR Fees
The class action lawsuit against CVS Health, Caremark, and Aetna was announced earlier today.
FDA Approves Drop for Drug-Induced Dilation of the Pupils
Ryzumi is expected to be available in the first half of 2024. Pricing will be available around the time of launch.
What We are Reading: A Pioneer in GLP-1 Research Fights for Recognition
Svetlana Mojsov, Ph.D., was a key part of the team that discovered the function of the hormone glucagon-like peptide 1 (GLP-1) and its role in diabetes and weight loss.
Preservative-free Therapy Launches to Reduce Intraocular Pressure in Glaucoma
Iyuzeh can be stored at room temperature. It has a list price of $299 for a month’s supply.
FDA Assigns Review Date for Dupixent in Young Children with Eosinophilic Esophagitis
The FDA has assigned a target action date of Jan. 31, 2024, for Dupixent to treat children 1 to 11 years of age with the inflammatory condition eosinophilic esophagitis.
Potential Contamination Leads to Recall of VistaPharm’s Sucralfate
In patients who are immunocompromised, Bacillus cereus can result in life-threatening infections such as endocarditis and necrotizing soft tissue infections.
2 Clarke Drive Cranbury, NJ 08512